ShuchiGulatiMDMSc, FACP
Oncology • Sacramento, CAGenitourinary Oncology
Assistant Professor, Hematology and Oncology, University of California Davis Comprehensive Cancer Center
Dr. Gulati is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
UC Davis Comprehensive Cancer Center
4501 X Street
Sacramento, CA 95817
Education & Training
University of Cincinnati Medical Center/College of MedicineFellowship, Hematology and Medical Oncology, 2015 - 2018
Tower HealthResidency, Internal Medicine, 2010 - 2012
Cleveland Clinic Foundation/Fairview HospitalInternship, Internal Medicine, 2009 - 2010
Indira Gandhi Medical CollegeClass of 2008
Certifications & Licensure
CA State Medical License 2022 - 2026
OH State Medical License 2009 - 2023
PA State Medical License 2010 - 2012- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
Publications & Presentations
PubMed
- 15 citationsAdvanced biliary tract cancer: clinical outcomes with ABC-02 regimen and analysis of prognostic factors in a tertiary care center in the United StatesRishi Agarwal, Arun Sendilnathan, Nabeela Iffat Siddiqi, Shuchi Gulati, Abhimanyu Ghose
Journal of Gastrointestinal Oncology. 2016-11-21 - 1212 citationsClinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.Nicole M. Kuderer, Toni K. Choueiri, Dimpy P. Shah, Yu Shyr, Samuel M. Rubinstein
Lancet. 2020-06-20 - 42 citationsPhase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma.Trisha M Wise-Draper, Shuchi Gulati, Sarah Palackdharry, Benjamin H Hinrichs, Francis P Worden
Clinical Cancer Research. 2022-04-01
Press Mentions
Adjuvant Everolimus Offers No Survival Benefit in Non–Clear Cell RCCAugust 30th, 2024- Study Compares the Cost and Efficacy of Anticoagulant TherapiesJanuary 4th, 2023
- Direct Oral Anticoagulants More Effective and Cost-Effective for Treating Cancer-Associated ThrombosisDecember 27th, 2022
- Join now to see all
Professional Memberships
- Associate
- Member
- SITCMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
